OUR PIPELINE
Advancing the science of veterinary therapeutics.
Building on medicines with years of human research behind them, we aim to bring selected programs to pets in significantly less time than a new animal drug typically takes. Every program is built for FDA approval from the start. Where a program may qualify, we also consider the conditional approval pathway.
A diversified pipeline across high-need indications.
We focus where human science is furthest ahead and veterinary need is greatest.
Plus 9 additional programs in early development across:
- Oncology
- Immunology and dermatology
- Neurology
- Kidney disease
- Metabolic disease
FAM-010 · Hemangiosarcoma
We are working toward the first FDA-approved treatment for hemangiosarcoma in dogs.
Hemangiosarcoma is one of the most aggressive cancers a dog can face. After surgery, vets usually turn to doxorubicin, a human chemotherapy that is not FDA-approved for use in dogs. It helps, but it strains the heart with every dose, so most dogs can only receive limited treatments before they have to stop, even when the cancer hasn't.
FAM-010 is designed to be gentler on the heart, so treatment can go further
FAM-010 is a new form of doxorubicin. It is attached to albumin, a natural protein in the blood, which is designed to carry the medicine to the tumor and release it there. Because less of the medicine reaches the rest of the body, we expect FAM-010 to be less toxic than standard doxorubicin, especially to the heart.
We are studying whether more medicine reaching the tumor, for a longer period of time, can potentially mean better control of the cancer and more time for dogs with the people who love them.
- Who it's for
- Dogs with hemangiosarcoma of the spleen, after surgery
- How it's given
- An infusion at the vet
- OUR PROGRESS
- Pilot study, enrolling soon at the University of Illinois
FAM-010 is investigational and not approved by FDA. FDA approval is not guaranteed.
FAM-010 CLINICAL STUDY
Trial enrollment is opening this fall.
Our FAM-010 pilot study opens soon at the University of Illinois, for dogs recently diagnosed with hemangiosarcoma of the spleen, at no cost to dog owners. Owners can check whether their dog may be eligible, and veterinarians can refer patients.
Follow our progress.
Be the first to hear when new studies open and our programs move forward.